[Asymptomatic atrial fibrillation with systematic screening using tele-ECG--relevance for anticoagulation in paroxysmal atrial fibrillation].

A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med (2002) 16.31

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet (2003) 9.13

A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med (2002) 8.37

Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet (1994) 5.37

Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation (1991) 4.52

Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA (2005) 3.54

Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J (2004) 2.78

Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. J Am Coll Cardiol (1995) 2.52

Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation (1994) 2.10

Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart (2005) 1.88

Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J (2005) 1.60

Suppression of paroxysmal atrial tachyarrhythmias--results of the SOPAT trial. Eur Heart J (2004) 1.58

Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch Intern Med (2005) 1.42

Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J (2005) 1.40

Role of transtelephonic electrocardiographic monitoring in detecting short-term arrhythmia recurrences after radiofrequency ablation in patients with atrial fibrillation. J Am Coll Cardiol (2005) 1.27

Biochemical markers of coagulation activation in mitral stenosis, atrial fibrillation, and cardiomyopathy. Clin Cardiol (1997) 0.90

Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin. Heart (2005) 0.85

Control of serum lipids with soy protein. N Engl J Med (1995) 0.84